National Breast Cancer Coalition

NBCC's Clinical Trials Partnerships

Upcoming Clinical Trials for Women with Metastatic Breast Cancer

NBCC is currently partnering with BioMarin on clinical trials for women with metastatic breast cancer. Intervention offers the potential of improving the length and quality of life for patients already diagnosed with metastatic breast cancer. Trial accrual has begun.

NBCC advocates have been involved in many ways on clinical trials in the development of the protocols, as members of the Date Safety Monitoring Board, as reviewers of educational materials and consent forms and in conducting outreach activities to educate the public about the trials.

EMBRACA clinical trial for the PARP inhibitor BMN 673 (BioMarin)

  • Purpose of the study:   To evaluate the efficacy and safety of BMN 673 in the metastatic setting.
  • Eligibility:  Women with the BRCA1 or BRCA 2 mutation and locally advanced or metastatic breast cancer.  Other eligibility criteria and trial details can be found at  http://clinicaltrials.gov/ct2/show/NCT01945775.

NBCC is recruiting advocates to help educate the public and potential participants about these trials. If you are interested in helping NBCC’s outreach effort for any of these trials, please contact us at clinicaltrials@breastcancerdeadline2020.org